2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
A newer version of this guideline has been published: 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting (2024)
- Study type
- Clinical guideline
- Study name
- MASCC/ESMO 2016
- Source
- Annals of Oncology · 2016
In plain words
This article is a joint clinical guideline from two societies, MASCC and ESMO, on preventing nausea and vomiting caused by chemotherapy and radiotherapy. It also covers nausea and vomiting in people with advanced cancer. To find out which medicines or approaches are right for you, talk to your treating doctor.
Clinical significance and place in guidelines
Based on the information in the record, this document is the 2016 update of the MASCC and ESMO guideline and is the outcome of the 2015 Copenhagen consensus conference. The details of the recommendations are not given in the PubMed record. Before use in clinical practice, check the full text of the guideline and its newer versions.
Limitations
The PubMed record has no abstract. For this reason, the recommendations, levels of evidence and suggested drugs are not included in this card and must be taken from the full text of the paper and confirmed by a reviewing physician. Newer versions of this guideline may have been published.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.